Extended Data Fig. 5: BAY-876 administration enhances efficacy of αPD-L1 treatment. | Nature Cell Biology

Extended Data Fig. 5: BAY-876 administration enhances efficacy of αPD-L1 treatment.

From: SLC2A1+ tumour-associated macrophages spatially control CD8+ T cell function and drive resistance to immunotherapy in non-small-cell lung cancer

Extended Data Fig. 5

a,b,c,d,e,f, Summarized data of the proportion (left) and total numbers (right) of CD45+ cells (a), CD4+ T cells (b), NK cells (c), MDSCs (d), TAMs (e), and DCs (f) in each indicated group from LLC tumors following BAY-876 treatment with or without αPD-L1 antibody therapy (Combination group (n = 6) and the other groups (n = 5 each)). g, MC38 allograft tumor growth kinetics (left) and the endpoint measurement of tumor mass (right) in C57BL/6 J mice following BAY-876 treatment with or without αPD-L1 antibody therapy (αPD-L1 group (n = 6) and the other groups (n = 8 each)). h, B16-F10 allograft tumor growth kinetics (left) and the endpoint measurement of tumor mass (right) in C57BL/6 J mice following BAY-876 treatment with or without αPD-L1 antibody therapy (n = 5). Data are reported as mean ± s.e.m., and group differences were assessed by a two-tailed unpaired Student’s t test.

Source data

Back to article page